GET DAILY SIGNALSShuttle Pharmaceuticals (SHPH) Advances +15% Over 30 Days on AI Strategy Shift
Key Takeaways
- SHPH gained roughly 15% over the past 30 days, moving from about $4.71 on October 7, 2026, to $5.43 at the November 6 close.
- The stock extended a longer-term advance, rising approximately 24% over the trailing three-month period.
- Attention has focused on the company's shift to AI-driven drug discovery via its Molecule.ai platform following the wind-down of Ropidoxuridine trials in late 2025.
- As a micro-cap with a limited float, SHPH experiences above-average volatility, with sharp intraday moves amplifying short-term swings.
- Higher trading volume supported the October advance, signaling renewed interest in AI-related biotechnology names.
- For deeper data, review Shuttle Pharmaceuticals' Price Targets, Earnings, and Forecast on Tickeron's dedicated pages.
Company Background and Strategic Repositioning
Shuttle Pharmaceuticals Holdings, Inc. is a clinical-stage pharmaceutical company based in Gaithersburg, Maryland, founded in 2012 by faculty from the Georgetown University Medical Center. It originally focused on radiation sensitizers to enhance cancer radiation therapies, with Ropidoxuridine (IPdR) as its lead candidate for glioblastoma.
In November 2025, the company acquired substantially all assets of Molecule.ai, an AI platform for molecular discovery and early drug development, while ending its Ropidoxuridine trials. This move redirected efforts toward AI-augmented discovery. I think investors track SHPH for its positioning at the intersection of artificial intelligence and oncology, while also considering its micro-cap scale, limited resources, and early-stage status. I also checked this using Tickeron’s AI Screener to see how the stock compares to others in the industry.
Stock Performance Over the Past 30 Days and Quarter
Over the last 30 days, SHPH rose from a close of $4.71 on October 7, 2026, to $5.43 on November 6, 2026, for a gain of about 15.3%. The path was uneven, with a spike near $5.55 early in October followed by a pullback, plus a sharp intraday drop to $3.30 in late October before recovery.
The quarterly picture is also positive. Trading near $4.38 at the start of August 2026, the stock posted a trailing three-month gain of roughly 24%. The pattern shows elevated volatility with an upward bias, typical for a micro-cap drawing fresh attention.
Factors Behind the Recent 30-Day Move
The advance appears driven mainly by renewed interest in Shuttle's AI-focused drug discovery approach. After the Molecule.ai acquisition and the close of prior clinical work, the company now centers on a computational platform for molecular property prediction and early development. Periodic enthusiasm for AI in healthcare and biotech has lifted similar names.
Market structure adds to the price action. With about 4.76 million shares outstanding, a market cap in the tens of millions, and few full-time employees, modest changes in trading can lead to large percentage shifts. Sessions with volume over 100,000 shares during the October advance point to speculative interest rather than any single major announcement.
Drivers of the Quarterly Performance
The three-month gain ties to a broader story. The November 2025 Molecule.ai acquisition represented a key pivot from clinical radiosensitizer work to AI-enabled discovery. This shift also cut operating costs, with research and development expenses dropping sharply as the earlier trials concluded.
At the same time, wider market interest in artificial intelligence has created a supportive environment for small-cap companies with an AI angle, even at early commercial stages. The combination of strategic change, lower clinical spending, and sector AI momentum has backed the multi-month climb, interrupted by volatility spikes.
Key Areas to Monitor Going Forward
Investors following SHPH should pay attention to the next quarterly earnings report and any updates on Molecule.ai platform development and commercialization. Given minimal revenue and limited cash, capital raises and dilution risk stay important factors in the outlook.
Broader moves in AI-driven healthcare, such as regulatory views on AI-assisted tools, could shape sector sentiment. With the stock's low float and thin volume, liquidity and volatility risks will likely remain relevant for near-term behavior. None of this is a forecast; results will depend on execution, funding, and market conditions.
Reviewing Automated Trading Approaches
In my own analysis, I often review Tickeron's Trending AI Robots to identify automated strategies that fit current market conditions. The page highlights top-performing bots from a platform with hundreds of options across thousands of tickers, letting users filter by style, holding period, and performance metrics to match their own risk tolerance and objectives. Checking this resource provides a streamlined view of quantitative approaches that may complement manual research on names like SHPH.
Disclaimer
The information on this webpage is provided for general informational and educational purposes only and is not intended as investment advice, a recommendation to purchase or sell any security, or an offer or solicitation related to investments. It does not consider your personal financial situation, goals, or risk profile, and all investing carries inherent risks, including the possibility of losing your entire investment. For more details, please review our full disclaimer.
Momentum Indicator for SHPH turns positive, indicating new upward trend
SHPH saw its Momentum Indicator move above the 0 level on October 30, 2026. This is an indication that the stock could be shifting in to a new upward move. Traders may want to consider buying the stock or buying call options. Tickeron's A.I.dvisor looked at 65 similar instances where the indicator turned positive. In 58 of the 65 cases, the stock moved higher in the following days. The odds of a move higher are at 89%.
Technical Analysis (Indicators)
Bullish Trend Analysis
Following a +5.04% 3-day Advance, the price is estimated to grow further. Considering data from situations where SHPH advanced for three days, in 134 of 162 cases, the price rose further within the following month. The odds of a continued upward trend are 83%.
The Aroon Indicator entered an Uptrend today. In 27 of 45 cases where SHPH Aroon's Indicator entered an Uptrend, the price rose further within the following month. The odds of a continued Uptrend are 60%.
Bearish Trend Analysis
The 10-day RSI Indicator for SHPH moved out of overbought territory on October 16, 2026. This could be a bearish sign for the stock. Traders may want to consider selling the stock or buying put options. Tickeron's A.I.dvisor looked at 8 similar instances where the indicator moved out of overbought territory. In 8 of the 8 cases, the stock moved lower in the following days. This puts the odds of a move lower at 90%.
The Stochastic Oscillator demonstrated that the ticker has stayed in the overbought zone for 8 days. The longer the ticker stays in the overbought zone, the sooner a price pull-back is expected.
The Moving Average Convergence Divergence Histogram (MACD) for SHPH turned negative on October 21, 2026. This could be a sign that the stock is set to turn lower in the coming weeks. Traders may want to sell the stock or buy put options. Tickeron's A.I.dvisor looked at 34 similar instances when the indicator turned negative. In 31 of the 34 cases the stock turned lower in the days that followed. This puts the odds of success at 90%.
Following a 3-day decline, the stock is projected to fall further. Considering past instances where SHPH declined for three days, the price rose further in 50 of 62 cases within the following month. The odds of a continued downward trend are 90%.
SHPH broke above its upper Bollinger Band on October 07, 2026. This could be a sign that the stock is set to drop as the stock moves back below the upper band and toward the middle band. You may want to consider selling the stock or exploring put options.
Fundamental Analysis (Ratings)
The Tickeron Valuation Rating of 41 (best 1 - 100 worst) indicates that the company is fair valued in the industry. This rating compares market capitalization estimated by our proprietary formula with the current market capitalization. This rating is based on the following metrics, as compared to industry averages: P/B Ratio (1.349) is normal, around the industry mean (7.254). P/E Ratio (0.562) is within average values for comparable stocks, (0.575). Projected Growth (PEG Ratio) (0.000) is also within normal values, averaging (2.202). Dividend Yield (0.000) settles around the average of (0.061) among similar stocks. P/S Ratio (0.000) is also within normal values, averaging (181.047).
The Tickeron Price Growth Rating for this company is 55 (best 1 - 100 worst), indicating steady price growth. SHPH’s price grows at a higher rate over the last 12 months as compared to S&P 500 index constituents.
The Tickeron PE Growth Rating for this company is 97 (best 1 - 100 worst), pointing to worse than average earnings growth. The PE Growth rating is based on a comparative analysis of stock PE ratio increase over the last 12 months compared against S&P 500 index constituents.
The Tickeron SMR rating for this company is 98 (best 1 - 100 worst), indicating weak sales and an unprofitable business model. SMR (Sales, Margin, Return on Equity) rating is based on comparative analysis of weighted Sales, Income Margin and Return on Equity values compared against S&P 500 index constituents. The weighted SMR value is a proprietary formula developed by Tickeron and represents an overall profitability measure for a stock.
The Tickeron Profit vs. Risk Rating rating for this company is 100 (best 1 - 100 worst), indicating that the returns do not compensate for the risks. SHPH’s unstable profits reported over time resulted in significant Drawdowns within these last five years. A stable profit reduces stock drawdown and volatility. The average Profit vs. Risk Rating rating for the industry is 84, placing this stock worse than average.
Notable companies
Industry description
Market Cap
High and low price notable news
Volume
Fundamental Analysis Ratings
The average fundamental analysis ratings, where 1 is best and 100 is worst, are as follows
Advertisement
General Information
Industry PharmaceuticalsGeneric
Advertisement